Medical Oncology

ASH 2025

Questions discussed in this category

How does the CLL17 trial presented at ASH 2025 change current practice guidelines?

Should all CLL patients be candidates for fixed-duration treatments?

1 Answer available

What are your top takeaways in Myeloma from ASH 2025?

10 Answers available

What are your top takeaways in Classical Hematology from ASH 2025?

5 Answers available

What are your top takeaways in Hematologic Malignancies from ASH 2025?

6 Answers available

Does the recent publication of EPCORE FL-1 (Epcoritamab + R2) change your preferred 2L SOC for R/R FL?

Falchi et al., PMID 41371238.

1 Answer available

How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?

Aza/ven patients had better EFS/QoL with a greater proportion of patients who successfully got to a stem cell transplant. Provided that the OS data is...

1 Answer available

What are your top takeaways in Lymphoma from ASH 2025?

3 Answers available

After the MAJESTEC-3 results, and once approved, what is your approach to choosing between tec-dara vs. cilta-cel versus another triplet for multiple myeloma in first relapse?

4 Answers available

Papers discussed in this category

N Engl J Med, 2023 Jun 05

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

The New England journal of medicine, 2023 Dec 12

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

The New England journal of medicine, 2025 Dec 09

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Nature medicine, 2025 Feb 05

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Lancet (London, England), 2020 Apr 18

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

The New England journal of medicine, 2025 Dec 06

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

The New England journal of medicine, 2025 Dec 09

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

Blood, 2025 May 15

How I treat challenging transfusion cases in sickle cell disease.

Lancet (London, England), 2025 Dec 07

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Lancet (London, England), 2025 Dec 05

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Medical Oncology

ASH 2025

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology